ArticleScientific reports2021

Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement.

Paweł Krawczyk et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.